PharmEasy plans to raise USD 200 million at lower valuations - Video
|
Overview
Indian drug and medical services startup PharmEasy is in talks with investors to raise $200 million, but at a valuation that could be 15% or even 25% lower than last year's $5.1 billion, two people with direct knowledge of deal talks told the media agency.
Signalling growing stress in India's startup ecosystem, one source said PharmEasy, backed by big-name investors such as Prosus, TPG and Temasek, is in talks to secure the new funds at a valuation as much as 15% below last year's.
For more details, check out the full story on the link below:
Speakers
Rahul Verma joined Medical Dialogues in the year 2022 and is currently working as a Video editor & Medical correspondent. He has completed his graduation in Bachelors of Arts (BA) from IGNOU. He likes to keep himself and the world updated on the occurring in the medical field. He can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751
